Paradigm Therapeutics

SC - Mount PleasantBiotechnologySponsors Visas

Focus: Paradigm Therapeutics is a South Carolina-based biotech focused on topical therapies across oncology and infectious disease indications. The company operates at a pre-revenue stage with a pipeline spanning dermal creams, orthopedic devices, and cancer biomarker research.

Oncology Infectious Diseases

Profile data last refreshed 12h ago · AI intelligence enriched 1w ago

Open Jobs

Should You Work at Paradigm Therapeutics?

AI assessment

Paradigm is a high-risk, early-stage bet suitable only for risk-tolerant candidates seeking rare-disease impact; the thin hiring pipeline and opaque financial footing suggest limited career infrastructure and runway uncertainty.

Why Work Here

SD-101 Dermal Cream for Epidermolysis Bullosa is in Phase 3, representing a near-term catalyst for clinical advancement in a rare disease with unmet need.

Data completeness

2/9 — Limited

Company HealthStrong

Pipeline

Late-stage

3 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

Stable

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

Transforaminal lumbar interbody fusion surgery

Degenerative Disc Disease Lumbar

N/A

Clinical Trials (1)

NCT07834931PMCF Study Fortilink-TC Ti

N/A

Help build intelligence for Paradigm Therapeutics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Pipeline spans multiple therapeutic areas (oncology, infectious disease, orthopedics, spinal conditions) offering cross-functional learning opportunities.

Early-stage biotech trajectory allows hands-on impact on drug development and potential equity upside if programs advance.

Watch Out For

Only 1 active job opening signals minimal hiring momentum and limited career mobility within the organization.
Pre-revenue status with no disclosed funding, financials, or employee count raises sustainability and long-term stability concerns.
Pipeline is heavily diluted across 17 trials with mixed phases (4 Phase 3, 1 Phase 2/3, rest in exploratory stages); many pipeline entries appear to be observational or methodological rather than therapeutic asset development.

Generated by Claude from Paradigm Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Decompression

Intermittent Neurogenic Claudication (INC) as a Result of Spinal Stenosis

N/A

Clinical Trials (1)

NCT01727752A Randomized Controlled Trial Comparing Surgical Decompression With an Interlaminar Implant in Patients With Intermittent Neurogenic Claudication Caused by Lumbar Stenosis

N/A

Posterior lumbar interbody fusion surgery

Degenerative Disc Disease Lumbar

N/A

Clinical Trials (1)

NCT07834736PMCF Study Fortilink-TS Ti

N/A

Cervical interbody fusion surgery

Degenerative Disc Disease in Cervical Spine

N/A

Clinical Trials (1)

NCT07834749PMCF Study Fortilink-SC

N/A

blood and tissue samples

Muscle Invasive Bladder Urothelial Carcinoma

N/A

Clinical Trials (1)

NCT06605404Pan-tumor MRD Study

N/A

Pentosan Polysulphate Sodium

Osteoarthritis, Knee

N/A

Clinical Trials (1)

NCT04814719Treatment and Duration Effect of Pentosan Polysulfate Sodium (PPS) in Participants With Knee Osteoarthritis Pain

N/A

Saliva collection

Covid19

N/A

Clinical Trials (1)

NCT04567953COVID-19 Tests With Saliva Specimens

N/A

Implantation of coflex™ after surgical decompression

Spinal Stenosis

N/A

Clinical Trials (1)

NCT01316211Clinical Trial Comparing Decompression With and Without Coflex™ Interlaminar Technology Treating Lumbar Spinal Stenosis

N/A

CT Scan

Spinal Fractures

N/A

Clinical Trials (1)

NCT02918669Study to Investigate the Long Term Survivorship of Coflex

N/A

Characterization of Human Cancers by Molecular Profiling of Patient Biospecimens

Cancer

N/A

Clinical Trials (1)

NCT02749838Characterization of Human Cancers by Molecular Profiling of Patient Biospecimens

N/A

coflex® Interlaminar Technology

Spinal Stenosis

N/A

Clinical Trials (1)

NCT03041896Retrospective Evaluation of Performance of Coflex® Interlaminer Technology Versus Decompression With or Without Fusion

N/A

Dynamic Stabilization System

Spondylolisthesis

N/A

Clinical Trials (1)

NCT01461005A Postmarket Surveillance Study of the Paradigm Spine Dynamic Stabilization System (DSS)

N/A

Decompression

Spinal Stenosis

N/A

Clinical Trials (1)

NCT00534235Post-Approval Clinical Trial Comparing the Long Term Safety and Effectiveness Coflex vs. Fusion to Treat Lumbar Spinal Stenosis

N/A

Pentosan Polysulfate Sodium twice weekly

Osteoarthritis, Knee

Phase 2/3

Clinical Trials (1)

NCT04809376Treatment Effects of Subcutaneous Injections of Pentosan Polysulfate Sodium vs Placebo in Participants With Knee OA Pain

Phase 2/3

Pentosan Polysulfate Sodium twice weekly

Osteoarthritis, Knee

Phase 3

Clinical Trials (1)

NCT06917404A Study to Investigate the Treatment Effect of Subcutaneous Injections of Pentosan Polysulfate Sodium Compared With Placebo in Adult Participants With Knee Osteoarthritis Pain.

Phase 3

SD-101 Dermal Cream

Epidermolysis Bullosa (EB)

Phase 3

Clinical Trials (1)

NCT07482813An Open Label Extension Safety Study to Evaluate SD-101 in Epidermolysis Bullosa

Phase 3

SD-101 Dermal Cream

Epidermolysis Bullosa (EB)

Phase 3

Clinical Trials (1)

NCT07482787Efficacy and Safety Study to Evaluate SD-101 in Epidermolysis Bullosa

Phase 3

Interview Prep Quick Facts

Portfolio: 17 clinical trials

Top TAs: Oncology, Gastroenterology, Infectious Diseases

Open Roles: 1 active job

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

Oncology

2 pipeline

Gastroenterology

1 pipeline

Infectious Diseases

1 pipeline

Marketed

Pipeline

Hiring Trend

Stable

Open Roles

Added

-0

Filled/Removed

Based on last 4 crawl cycles

Visa Sponsorship

Sponsors Work Visas

H-1B Petitions (FY2023)

Approved

Denied

Rate

Source: USCIS H-1B Employer Data Hub

Paradigm Therapeutics

Should You Work at Paradigm Therapeutics?

Why Work Here

Pipeline & Clinical Trials

Watch Out For

Open Jobs (1)

General Application

Hiring Trend

Visa Sponsorship